Molekulargenetik der akuten myeloischen Leukämie mit Kernbindungsfaktor

Recent innovations in molecular biology, genetics, and cell biology have revolutionized the understanding of disease development and the efforts to discover novel biomarkers and drug targets, ultimately leading to the development of more effective medications with fewer side effects. A particular focus of these groundbreaking approaches has been on leukemia and other blood cancers, with the discovery of many new cancer-causing genes and therapies that directly target cancer cells and oncogenes. In acute myeloid leukemia (AML), there have been significant advancements in early diagnosis, molecular subclassification of the disease, prognostic stratification, and the discovery of new drugs, culminating in a personalized treatment approach for AML patients. This book provides an overview of the biology and genetic foundations of AML and their significance for clinical practice and research.